285 related articles for article (PubMed ID: 10446980)
1. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
[TBL] [Abstract][Full Text] [Related]
2. In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
Tesei A; Ricotti L; De Paola F; Amadori D; Frassineti GL; Zoli W
Clin Cancer Res; 2002 Jan; 8(1):233-9. PubMed ID: 11801564
[TBL] [Abstract][Full Text] [Related]
3. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
5. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
[TBL] [Abstract][Full Text] [Related]
6. Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S; Takenaka K; Sonobe M; Wada H; Tanaka F
Chemotherapy; 2008; 54(3):166-75. PubMed ID: 18560222
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
Rodenbach M; Eyol E; Seelig MH; Berger MR
J Cancer Res Clin Oncol; 2005 May; 131(5):289-99. PubMed ID: 15657768
[TBL] [Abstract][Full Text] [Related]
8. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
Wouters A; Pauwels B; Lardon F; Pattyn GG; Lambrechts HA; Baay M; Meijnders P; Vermorken JB
BMC Cancer; 2010 Aug; 10():441. PubMed ID: 20723210
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
Adjei AA; Erlichman C; Sloan JA; Reid JM; Pitot HC; Goldberg RM; Peethambaram P; Atherton P; Hanson LJ; Alberts SR; Jett J
J Clin Oncol; 2000 Apr; 18(8):1748-57. PubMed ID: 10764436
[TBL] [Abstract][Full Text] [Related]
10. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
Teicher BA; Alvarez E; Liu P; Lu K; Menon K; Dempsey J; Schultz RM
Semin Oncol; 1999 Apr; 26(2 Suppl 6):55-62. PubMed ID: 10598556
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
12. Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.
Adjei AA
Semin Oncol; 2002 Dec; 29(6 Suppl 18):30-4. PubMed ID: 12571808
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
[TBL] [Abstract][Full Text] [Related]
14. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Misset JL
Semin Oncol; 2002 Feb; 29(1 Suppl 3):36-9. PubMed ID: 11894006
[TBL] [Abstract][Full Text] [Related]
15. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
16. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.
Mercalli A; Sordi V; Formicola R; Dandrea M; Beghelli S; Scarpa A; Di Carlo V; Reni M; Piemonti L
Br J Cancer; 2007 May; 96(9):1358-67. PubMed ID: 17426706
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin.
Thödtmann R; Depenbrock H; Dumez H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
J Clin Oncol; 1999 Oct; 17(10):3009-16. PubMed ID: 10506594
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Mey V; Giovannetti E; De Braud F; Nannizzi S; Curigliano G; Verweij F; De Cobelli O; Pece S; Del Tacca M; Danesi R
Br J Cancer; 2006 Aug; 95(3):289-97. PubMed ID: 16868547
[TBL] [Abstract][Full Text] [Related]
19. The pemetrexed/gemcitabine combination in pancreatic cancer.
Kindler HL
Cancer; 2002 Aug; 95(4 Suppl):928-32. PubMed ID: 12209673
[TBL] [Abstract][Full Text] [Related]
20. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
